Risk Factors for Community- and Workplace Transmission of COVID-19
調査の概要
詳細な説明
Summary The data collected will identify real-life risk factors for getting the COVID-19 diagnosis.
The Oslo University Hospital/University of Oslo web-based solution "nettskjema" will be used to collect data and consent forms.
The impact of knowing the risk factors for COVID-19 is tremendous because it can enable governments to conduct more targeted public health measurements than today to reduce the spread of the virus.
Detailed description Research into an ongoing COVID-19 outbreak is difficult because patients are isolated, and supplies of personal protective equipment (PPE) supplies are limited. The risk of transmission to study personal is non-negligible even when PPE is available.
A study design based on an electronic questionnaire and consent from delivered from the Oslo University Hospital/University of Oslo, GDPR (General Data Protection Regulation) compliant "TSD" service has therefore been chosen.
The study will be a case-control study based on a combined electronic consent form and questionnaire that the participants will fill in using a smartphone and electronic identification.
The groups that will be included are:
- Hospitalized and non-hospitalized patients/persons with COVID-19 at all stages of the disease and after the disease
- Hospitalized patients without COVID-19
- Healthcare personal or other groups with an increased risk of COVID-19
- Healthy volunteers
Participants may be followed with repeated questionnaires prospectively.
Biological samples Biological samples may hold crucial information about the susceptibility to COVID-19 and for susceptibility to the progression of the disease. It is within the scope of the study to analyze such samples from a limited number of participants which will be asked to provide such samples or hospitalized patients that have surplus material. The material will be analyzed with non-genetic methods most suitable to provide such information.
研究の種類
入学 (予想される)
連絡先と場所
研究連絡先
- 名前:Arne Søraas, MD, PhD
- 電話番号:+4790652904
- メール:Arne.Vasli.Lund.Soraas@rr-research.no
研究連絡先のバックアップ
- 名前:John Arne Dahl, PhD
- メール:j.a.dahl@medisin.uio.no
研究場所
-
-
-
Oslo、ノルウェー、0424
- 募集
- Oslo University Hospital
-
コンタクト:
- John A Dahl, PhD
- 電話番号:+4741456596
- メール:j.a.dahl@medisin.uio.no
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
The study will be a combined retrospective and prospective case-control study based on a combined electronic consent form and questionnaire that the study groups will fill in using a smartphone and electronic identification.
The groups that will be included are:
- Hospitalized and non-hospitalized patients/persons with COVID-19 at all stages of the disease and after the disease
- Hospitalized patients without COVID-19
- Healthcare personal or other groups with an increased risk of COVID-19
- Healthy volunteers
Probability sampling will be conducted, but not solely.
説明
Inclusion Criteria:
- Norwegian adult
Exclusion Criteria:
- Unable to consent
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Individuals with COVID-19 infection
Confirmed by routine laboratory diagnosis. All types of COVID-19 disease from asymptomatic carriers to hospitalized patients can be included. Only subjects >18 years old will be included in the study. |
No intervention, only prospective observation of behavior will be conducted by a questionnaire.
|
|
Individuals tested for COVID-19 infection with negative test
Confirmed by routine laboratory diagnosis
|
No intervention, only prospective observation of behavior will be conducted by a questionnaire.
|
|
Healthy individuals
Recruitet from the general population
|
No intervention, only prospective observation of behavior will be conducted by a questionnaire.
|
|
Risk groups for COVID-19 exposure
Including, but not limited to healthcare workers.
|
No intervention, only prospective observation of behavior will be conducted by a questionnaire.
|
|
Patients admitted to hospital
Without COVID-19 infection.
|
No intervention, only prospective observation of behavior will be conducted by a questionnaire.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Rate of COVID-19 infection
時間枠:1 year
|
Diagnosed with serology or direct viral detection
|
1 year
|
協力者と研究者
スポンサー
協力者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- REK-124170
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。